on NICOX (EPA:COX)
Nicox launches FAQ page for shareholders
On August 26, 2025, Nicox SA, an ophthalmology company, announced the addition of a "Questions and Answers" page to its website. This page aims to answer shareholders' frequently asked questions about the company and its activities. Investors can also send their questions by email.
Nicox, listed on Euronext Growth Paris, develops innovative solutions for eye health. Its flagship program, NCX 470, is an eye drop designed to reduce intraocular pressure in patients with glaucoma. Other projects, such as NCX 1728 in collaboration with Glaukos, are underway.
The online presence of this new section facilitates access to information for shareholders and illustrates Nicox's commitment to transparency. Interested parties can consult the dedicated page for more details.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NICOX news